Clinical Trial Detail

NCT ID NCT03851614
Title Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto

colorectal cancer

pancreatic adenocarcinoma



Cediranib + Durvalumab

Durvalumab + Olaparib

Age Groups: adult senior

No variant requirements are available.